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Pipeline Flex Embolization Device (PED Flex) for the treatment of intracranial
aneurysms: Periprocedural outcomes and first-year angiographic results
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Background/aim: The Pipeline Flex Embolization Device (PED Flex) is a new updated version of the PED classic that incorporates a
new delivery system to allow facilitation of stent deployment, resheathing, and removal of the capture coil. This study evaluated the PED
Flex in terms of the technical aspects of the procedure and first-year follow-up results.
Materials and methods: This retrospective study involved prospectively collected data from May 2015 to August 2017. The primary
endpoint was technical aspects of the procedure, and the secondary endpoint was first-year follow-up results.
Results: Forty-nine patients with 59 target intracranial aneurysms were enrolled. Patients’ mean age was 52 years (range 21−71 years),
and 31 (63.0%) were female. All aneurysms except for three were unruptured. The mean aneurysm diameter was 8 mm. Forty-seven
patients with 56 aneurysms were successfully treated. Due to advancement, repositioning, and migration problems, 8 (13.1%) stents
were not deployed and discharged. The total aneurysm occlusion rate was 77.0%. The mortality rate was 4.3%.
Conclusion: Our experience shows that the applicability and safety of the renewed delivery system provided by PED Flex for improving
device apposition and opening has been proven with one-year angiographic and clinical follow-up results.
Key words: PED Flex, intracranial aneurysm, endovascular treatment

1. Introduction
The Pipeline Embolization Device (PED) (Medtronic
Neurovascular, Irvine, CA, USA) is one of the most widely
used flow diverter stents for the treatment of intracranial
aneurysms. Its safety and efficacy have been reported
by the “Pipeline for Uncoilable or failed aneurysms:
results from a multicenter clinical trial” (PUFS trial) [1]
and the “International Retrospective Study of the PED:
a multicenter aneurysm treatment study” (IntrePED
study) [2], with a high rate of occlusion of aneurysms in
the internal carotid artery (ICA) and a low rate of major
events. The device has been routinely employed in the
treatment of all intracranial aneurysms, with increasing
use in small and more distal intracranial aneurysms [3,4].
The PED received the European CE mark of approval
in 2008 and US Food and Drug Administration (FDA)
approval in 2011 and is now considered first-generation.
The first-generation PED can be technically
challenging, particularly in an anatomically tortuous
parent vessel. Problems often encountered during PED
placement include difficulty in freeing the distal end

of the device from a constrained capture coil, limited
pushability of the delivery wire, inconsistent deployment,
misplacement, stent narrowing, and inability to resheath
the PED after partial deployment [5].
The Pipeline Flex Embolization Device (PED Flex)
received the European CE mark of approval in March
2014 and FDA approval in February 2015. The Pipeline
Flex contains a completely redesigned delivery system,
while the stent device remains unchanged. The new
delivery system provides the following advantages: the
proximal portion has a resheathing pad to allow for
recapture and repositioning of the device after partial
deployment, and the distal portion has two constraining
protective sleeves that allow for increased convenience of
the device opening and facilitation of stent resheathing by
180° rotation upon device recapture. The pusher is also
larger, with a more robust laser-cut hypotube to enhance
the pushability of the device during delivery [6]. All these
changes in the PED delivery system should result in easier
device deployment, potentially improving procedural
outcomes.
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The new delivery system of the PED Flex entails
numerous innovations for stent deployment. This study
retrospectively evaluated 49 patients with 59 aneurysms
treated using the PED Flex. The technical aspects of the
procedure, such as the number of resheathing attempts,
technical success outcomes, and procedure-related adverse
events, were assessed as the primary endpoint, while firstyear follow-up results served as the secondary endpoint.
2. Methods
This retrospective study from two centers was performed
from May 2015 to August 2017. Forty-nine patients with
59 target intracranial aneurysms were enrolled. Written
and signed informed consent was obtained from each
patient. The study was approved by the institutional review
board responsible for all patient data and images available
in the hospital information system. All procedures were
performed by interventional radiologists using a biplane
flat panel angiographic system (Artis Q and Zee, Siemens,
Erlangen, Germany).
In preparation for the procedure patients were treated
with a dual antiplatelet regimen (clopidogrel 75 mg/
prasugrel 10 mg and aspirin 300 mg daily). If an adequate
platelet response was not achieved with clopidogrel,
increased daily doses (e.g. 150 mg clopidogrel daily)
were administered. If clopidogrel resistance was detected,
clopidogrel was replaced with prasugrel. All procedures
were performed under general anesthesia and systemic
anticoagulation was provided during the procedure.
Aneurysms were categorized according to location and
size (small <10 mm, 25 mm ≥ large ≥ 10 mm, and giant
>25 mm) (Table 1). We treated three ruptured aneurysms
in our case series, one of which resulted in mortality due
to a second bleed on the 27th day following the procedure.
The PED Flex was deployed through a microcatheter
(Marksman; Stryker, Neurovascular, California, USA or
Rebar 27; ev3/Covidien, Massachusetts, USA) using a
triaxial system. Balloon angioplasty was performed in the
case of incomplete stent apposition or insufficient opening
of the distal or proximal portion of the stent. A suitable
size of HyperForm/HyperGlide balloon (ev3/Covidien,
Irvine, California, USA) was employed for the parent
vessel. Angiographic follow-up was scheduled at 6 months,
1 year, 2 years, and 5 years after treatment and results were
given according to first year follow-up.
Patient demographics and aneurysm characteristics
were recorded. The primary endpoints were the technical
aspects of the procedure, such as the number of resheathing
attempts, use of the balloon to exact apposition, device
deployment success rates, and procedure-related adverse
events. The secondary endpoint was the first-year followup aneurysm occlusion rate based on the O’Kelly–Marotta
(OKM) grading scale (A, complete filling; B, subtotal

Table 1. Patient demographics and characteristics of target
aneurysms.
Patients

n: 49

Mean age (range), years

52 (21–71)

Female

31 (63%)

Aneurysms number

n: 59

Location
Anterior circulation

52 (88%)

Internal carotid artery

43

Petrous segment

1

Cavernous segment

6

Paraophthalmic segment

17

Supraclinoid segment

19

Anterior cerebral artery

6

Middle cerebral artery

3

Posterior circulation

7 (12%)

Size (mean diameter, mm)

8

Small, n (%)

40 (67.9%)

Large, n (%)

18 (30.5%)

Giant, n (%)

1 (1.6%)

filling; C, entry remnant; and D, no filling) [7], in-stent
stenosis, and morbidity/mortality rates.
3. Results
Forty-nine patients with 59 target intracranial aneurysms
were included in this study. Patients’ mean age was 52
years (range 21−71 years), and 31 (63.0%) were female.
All aneurysms except for three were unruptured, and
ruptured aneurysms were treated two weeks subsequently
for subarachnoid hemorrhage (SAH). The mean maximal
aneurysm diameter was 8 mm (range 2–25 mm). Fifty-six
aneurysms were saccular, two were dissecting, and one was
a pseudoaneurysm, which was secondary to a previously
treated carotid cavernous fistula (Figure 1). The majority of
the aneurysms (n = 52) were located in the ICA. Nine were
located beyond the internal carotid artery termination,
and seven were located in the posterior circulation (Table
1). Forty-two patients had one aneurysm, while the other
seven had multiple aneurysms. There were 23 cortical
branches covered by the device, but we had 18 cortical
branches in first-year follow-up (Table 2).
Eight stents in eight patients could not be deployed
because of a stent advancement problem or an unsuccessful
resheathing attempt. Five stents encountered a problem
with stent advancement into the Marksman microcatheter
and were entirely removed using the microcatheter. A twist
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Figure 1. A 21-year-old man previously treated using a detachable balloon (GOLD
BAL1, Balt Extrusion, Montmorency, France). a) Follow-up revealed a dissecting
aneurysm 14 × 15 mm in size in the right ICA cavernous segment. b) A 4.5 × 16
mm PED Flex was deployed into the ICA, and flow into the aneurysm was markedly
slower after the procedure. c) Dyna CT images show a well-opened stent and contrast
medium stagnation (arrow) in the aneurysmal sac. d) A first-year control DSA image
demonstrating complete occlusion of the aneurysm and full patency of the stent.

in the stent occurred in one of these cases. Resheathing
or recapturing was attempted with seven devices and
was successful in four. Resheathing was performed for
repositioning in two stents and for insufficient opening
of the distal part of the stent in two cases. Resheathing
failed at two attempts at repositioning, and the stents were
removed. In these cases, recatheterization was required
due to retrograde proximal displacement of the stent and
microcatheter, and a second stent had to be used. The
stent could not be deployed in two patients, and treatment
using the PED Flex was unsuccessful. The unsuccessful
treatment rate was 4.1% (2/49). In conclusion, 47 patients
with 56 aneurysms were treated. Altogether, 61 devices
were used in this study, 53 of which were deployed to the
target site. Eight (13.1%) stents could not be deployed
and discharged due to advancement, repositioning, and
migration problems.
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Second instruments were used in 14 cases in our series
in order to improve stent apposition with the balloon or to
prevent early rupture with the coil. Adjunctive moderate
coil packing was performed in nine cases. Balloon
angioplasty was performed in five cases due to lack of stent
apposition or insufficient opening of the distal/proximal
part of the stent. In one of them, balloon angioplasty
was performed to improve the flow of the covered
cortical branches. We used the HyperForm or HyperGlide
balloon (ev3/Covidien, Irvine, California, USA) in a size
appropriate to the parent vessel.
Intraprocedural or periprocedural thromboembolic
events occurred in four (8.1%) patients. All these presented
with minor neurological deficits, and there were no clinical
deficits at discharge. We had two groin complications
(femoral pseudoaneurysm and retroperitoneal hematoma).
One patient died due to a massive retroperitoneal
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Table 2. Aneurysm occlusion rates, in-stent stenosis, and states
of related cortical branches at first-year follow-up.
Aneurysm occlusion

n: 39

A (complete filling)

4 (10.2%)

D (subtotal filling)

0 (0.0%)

C (entry remnant)

5 (12.8%)

D (no filling)

30 (77.0%)

In-stent stenosis

n: 35

Fully patent

28 (80.1%)

Mild (≤ 50%)

5 (14.8%)

Moderate (50%–70%)

2 (5.1%)

Severe (≥ 70)

0 (0.0%)

Cortical branches

n: 18

Patent

11 (61.1%)

Very narrow

2 (11.1%)

Occluded

5 (27.8%)

hematoma secondary to postprocedural femoral access
bleeding in the intensive care unit.
The first-year follow-ups of 32 patients with 36
aneurysms were assessed using control digital subtraction
angiography (DSA) images. The occlusion rate of the
aneurysm, the patency of the stent, and the adjacent cortical
branches of the aneurysms were evaluated. The total
aneurysm occlusion rate was 77.0% at first-year follow-up.
Four aneurysms were grade A (complete filling), five were
grade C (entry remnant), and 30 aneurysms were grade D
(no filling). Seven cases of in-stent stenosis were observed,
five (14.8%) mild and two (5.1%) moderate. Eighteen
cortical branches covered by the stent were evaluated.
Eleven of these were patent, two were decreased in caliber
(Figure 2), and five were totally occluded (Table 2).
The morbidity rate in our case series was 0.0%, although
the mortality rate was 4.3%. Mortality was secondary to
complications of femoral artery access and second bleed
in the SAH patient, and was not related to the PED Flex or
neurological ischemic complications.
4. Discussion
The renewed delivery system of the PED Flex has been
previously reviewed in the literature [5,8−12,15,20].
While some studies evaluated the delivery system, the
detail of the redesign of the delivery system was not
discussed. We present our experience using the PED Flex
in 49 cases with 59 aneurysms in both the anterior and
posterior circulations. The successful treatment rate with
the PED Flex was 95.9% (47/49). Due to anatomic vessel
tortuosity, we were unable to treat two patients using the

PED Flex. Fifty-seven aneurysms were treated in 47 cases
with successful implantation of the PED Flex. The mean
number of devices used per patient was 1.25 (59/47), and
the mean number per aneurysm was 1.05 (59/56). In one
large case series, the equivalent rate for the previous PED
Flex per aneurysm was 1.3−1.4 [13,14]. However, the
success rate of the device deployment was 86.8%. Eight
(13.2%) devices were discharged or removed in our series.
Five were discharged due to inability to advance through
the microcatheter. We attempted to recapture or resheath
seven devices and were successful in four (57%) of these.
Martínez-Galdámez et al. [15] reported that resheathing
was attempted with 13 devices and was successful in 12
(92.3%). Lin et al. [16] reported a 13% discharge or removal
rate for the previous PED Flex. In one recent paper, the
PED Flex Shield (with the same delivery system as the
PED Flex) utilized a mean 1.12 devices per aneurysm, with
a failure to deploy rate of 5.4% [12].
The PED Flex was introduced as a redefined delivery
system consisting of new features. The new delivery
system primarily provides resheathing and repositioning
of the device after partial deployment. Resheathability and
removal of the capture coil were considered fundamental
innovations in the delivery system. These features make
device deployment and apposition easier, potentially
improving procedural outcomes. However, we also think
that the new delivery system requires a learning curve.
Pereira et al. described various technical nuances related to
the use of this system. The PED Flex is delivered through
simple application of an 80% pull to the microcatheter
and a 20% push to the wire. Pereira et al. reported that the
following two strategies can be used to initiate deployment:
1) the initial 10 mm is deployed distal to the target
lesion and the partially deployed device is subsequently
withdrawn to the planned landing zone; and 2) the device
is navigated to the landing zone and the microcatheter is
unsheathed progressively until deployment. If the distal
part of the stent cannot be opened secondary to the
attached protective leaves, the stent should be recaptured
to invert or release the leaves and then reopened [9].
Despite these innovations developed to improve stent
placement, balloon angioplasty was still required in four
cases (7.0%) in our series. Martínez-Galdámez et al. [15]
reported a figure of 18.0% (9/50) for adjunctive balloon
use. One study comparing PED and PED Flex reported a
10.5% (6/57) angioplasty rate in the PED group compared
to 2.6% (1/38) in the PED Flex group [10].
The total aneurysm occlusion rate at first-year followup in our series was 77.0%, the moderate/severe in-stent
stenosis rate was 5.1%, and the aneurysm-related branch
occlusion rate was 27.8%. The morbidity rate was 0.0%
and the mortality rate was 4.3%, although mortality was
not related to PED Flex (Table 2). The total aneurysm
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Figure 2. A 56-year-old woman with headache. a,b) Digital subtraction angiography
(DSA) and 3D-DSA images revealed saccular aneurysm originating from the
pericallosal and callosomarginal artery bifurcation. c) Angiographic image obtained
immediately after deployment of the 2.5 × 14 mm PED Flex into the anterior cerebral
artery A2 segment to cover the aneurysm neck. The image shows a decrease in the
passage of contrast medium into the aneurysm sac following the stent placement,
comparison to a. d) A first-year control DSA image demonstrating complete occlusion
of the aneurysm and full patency of the stent, although diameter of the callosomarginal
artery (arrow) decreased. The patient is currently asymptomatic at clinical follow-up.

occlusion rate was corroborated by previous studies
and metaanalyses [1,13,17,18]. In the PUFS study, the
moderate/severe (≥50%) in-stent stenosis rate during
the first year following the procedure was 2.2% (2/91).
In the same study, angiographic complete occlusion rate,
residual neck, and residual aneurysms were found to be
76.0%, 7.5%, and 5.7%, respectively, at 6 months followup, whereas the same rates were found to be 93.4%, 2.6%,
and 2.6%, respectively, at 3 years follow-up [1]. Oishi et
al. [19] found that complete occlusion rate, residual neck,
and residual aneurysms were found to be 69.2%, 19.2%,
and 9.6%, respectively, at one year follow-up in 52 of 100
large and giant unruptured aneurysms treated with PED.
In the aneurysm study of pipeline in an observational
registry (ASPIRe) study, the complete occlusion rate was
79.0% (15/19) at 1 year follow-up. Eleven (5.8%) patients
required retreatment [20]. Chalouhi et al. investigated in-
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stent stenosis in 139 patients treated using the PED (mean
follow-up 6.7 months, range 3−24 months) and reported
moderate/severe in-stent stenosis in 11 (7.9%) patients
[21]. Martínez-Galdámez et al. recently reported an 81.8%
total aneurysm occlusion rate at first-year follow-up in
their prospective study titled the PFLEX Study with Shield
Technology. The in-stent severe stenosis rate in that study
was 3.1% [12]. In the IntrePED study, the neurological
morbidity and mortality rate was 8.4%, the most common
adverse event being ischemic stroke due to thromboembolic
complications [2]. Two large metaanalyses of flow-diverter
treatment demonstrated morbidity rates of 5.0%–7.3%
and mortality rates of 2.8%–4.0% [17,18]. In the other
study involving the PED Flex, the 30-day morbidity rate
was 6.6%, with no deaths being reported [22]. One study
with a large case series comparing the PED Flex with
the new delivery system and the previous PED reported
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procedural success rates of 98% and 96%, respectively. The
complication rate was significantly lower, and the rate of
major morbidity or death was 5.6% for the previous PED
cases and 1.9% for the PED Flex cases [11]. The delivery
system of PED Flex provides an important innovation in
light of the current studies with high procedural success
rates and lower complication rates.
The limitations of this study include its retrospective
design, small patient population, and relatively small
mean aneurysm size.

The Pipeline embolization device has been renewed
and improved. Our experience shows that the applicability
and safety of the renewed delivery system offered by PED
Flex for improvement of device apposition and opening
are more beneficial than the first one in view of technical
and clinical results. Although the new delivery system
allows easier deployment, some technical aspects warrant
a period of training as part of the learning process.
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